CLPT CFO reports RSU vesting and share withholding

ClearPoint Neuro, Inc. Chief Financial Officer Danilo D'Alessandro reported equity award activity.

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Financial Officer Danilo D'Alessandro reported equity award activity. On March 3, 2026, he exercised 10,332 Restricted Stock Units, converting them into 10,332 shares of common stock, as part of a scheduled vesting. Following this, his directly held common stock position was 75,405 shares, and his remaining directly held Restricted Stock Units totaled 41,328 units. To cover tax withholding tied to the vesting, 5,257 shares of common stock were delivered to ClearPoint Neuro at a price of $8.84 per share in a tax-withholding disposition.

Insider Trade Summary

10,332 shares exercised/converted

Exercise 3 txns

Insider D'Alessandro Danilo

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	10,332	$0.00	$0.00
Exercise	Common Stock	10,332	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,257	$8.84	$46K

Holdings After Transaction: Restricted Stock Units — 41,328 contracts (Direct); Common Stock — 75,405 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CLPT CFO Danilo D'Alessandro report?

Danilo D'Alessandro reported the vesting and settlement of 10,332 Restricted Stock Units into 10,332 shares of ClearPoint Neuro common stock, plus a tax-withholding disposition of 5,257 shares delivered to the company at $8.84 per share to satisfy tax obligations.

How many ClearPoint Neuro shares does the CLPT CFO hold after these Form 4 transactions?

After these transactions, Danilo D'Alessandro directly holds 75,405 shares of ClearPoint Neuro common stock. He also directly holds 41,328 Restricted Stock Units, each representing a contingent right to receive one share of ClearPoint Neuro common stock upon future vesting events.

What do the 10,332 Restricted Stock Units reported by CLPT’s CFO represent?

Each of the 10,332 Restricted Stock Units represents a contingent right to receive one share of ClearPoint Neuro common stock. The reported transaction reflects settlement of these units into common shares on their scheduled vesting date, as disclosed in the accompanying footnote explanation.

Why were 5,257 CLPT shares delivered back to ClearPoint Neuro in this filing?

The 5,257 shares of ClearPoint Neuro common stock were delivered to the company to satisfy applicable tax withholding obligations. This tax-withholding disposition occurred in connection with the vesting of Restricted Stock and used a per-share value of $8.84.

What types of securities are involved in the CLPT CFO’s latest Form 4?

The filing covers Restricted Stock Units and common stock of ClearPoint Neuro. Restricted Stock Units were exercised or converted into common shares, and a portion of those common shares was subsequently used in a tax-withholding disposition to meet associated tax obligations at vesting.

Is the CLPT CFO’s Form 4 primarily a purchase or sale of shares?

The Form 4 reflects a mix of actions: an exercise or conversion of 10,332 Restricted Stock Units into common stock and a related tax-withholding disposition of 5,257 shares. It documents equity award vesting activity rather than an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Alessandro Danilo

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		10,332	A	(1)	80,662	D
Common Stock	03/03/2026		F		5,257(2)	D	$8.84	75,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/03/2026		M			10,332	(1)	(1)	Common Stock	10,332	(1)	41,328	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.